← Leaderboards
Andres Mario Salazar
Oncovir, Inc.
$2,299,168
Attributed
$2,427,859
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $732.2K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$2,427,859 · 3
By mechanism
R44$1,689,340 · 1
R01$481,137 · 1
R43$257,382 · 1
Top collaborators
- Mary P Stenzel-Poore1 shared
Others in their field
Top investigators on “Immunomodulators”
- Fred M Gordin · Social And Scientific Systems, Inc.$75,931,872
- Johnnye L Lewis · University Of New Mexico$18,505,537
- Rama Rao Amara · Emory University$16,402,105
- Eric Hunter · University Of Alabama At Birmingham$16,402,105
- Robert H Squires · Children'S Hosp Pittsburgh/Upmc Hlth Sys$16,267,601
- Sumit K Chanda · Scripps Research Institute, The$14,981,889
Research focus
ImmunomodulatorsIncidenceImmune ResponseHistologicAdaptive ImmunityBloodCancer PatientAntigensHead And Neck CancerClinically SignificantClinical ResearchAntiviral AgentsDesignDisease ProgressionDisease RegressionDisorder ControlBaseDouble-Stranded RnaCessation Of LifeBiopsyElementsEvaluationFollow-UpIndustry
Grant awards (5)
In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study$732,170
R44 · FY2017 · CA · contact PI
In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study$732,170
R44 · FY2016 · CA · contact PI
In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study$225,000
R44 · FY2014 · CA · contact PI
Hiltonol provides potent neuroprotection from ischemic brain injury in stroke.$257,382
R43 · FY2013 · NS · contact PI
Poly-ICLC Prophylaxis Treatment of Ebola Virus Infection$481,137
R01 · FY2005 · AI